Page 345 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 16 Supportive Care for the Cancer Patient 323

163. Serafini AN: Therapy of metastatic bone pain, J Nucl Med 42:895– 187. Fidel J, Lyons J, Tripp C, et al.: Treatment of oral squamous cell
906, 2001. carcinoma with accelerated radiation therapy and concomitant car-
164. Patchell RA, Tibbs PA, Regine WF, et al.: Direct decompressive boplatin in cats, J Vet Intern Med 25:504–510, 2011.
VetBooks.ir surgical resection in the treatment of spinal cord compression 188. Bateman KE, Catton PA, Pennock PW, et al.: 0–7–21 radiation
therapy for the treatment of canine oral melanoma, J Vet Intern Med
caused by metastatic cancer: a randomised trial, Lancet 366:643–
648, 2005.
8:267–272, 1994.
165. Chow E, Fan G, Hadi S, et al.: Symptom clusters in cancer patients 189. Blackwood LDJ: Radiotherapy of oral malignant melanomas in
with brain metastases, Clin Oncol 20:76–82, 2008. dogs, J Am Vet Med Assoc 209:98–102, 1996.
166. Mantyh PW: Bone cancer pain: from mechanism to therapy, Curr 190. Freeman KP, Hahn KA, Harris FD, et al.: Treatment of dogs with
Opin Support Palliat Care 8:83–90, 2014. oral melanoma by hypofractionated radiation therapy and plati-
167. Sabino MAMP: Pathophysiology of bone cancer pain, J Support num based chemotherapy, J Vet Intern Med 17:96–101, 2003.
Oncol 3:15–24, 2005. 191. Proulx DR, Ruslander DM, Dodge RK, et al.: A retrospective anal-
168. Jimenez-Andrade JM: Pathological sprouting of adult nociceptors ysis of 140 dogs with oral melanoma treated with external beam
in chronic prostate cancer-induced bone pain: editorial comments, radiation, Vet Radiol US 44:352–359, 2003.
J Urol 186:342, 2011. 192. Murphy S, Hayes AM, Blackwood L, et al.: Oral malignant mela-
169. Jimenez‐Andrade JM, Mantyh WG, Bloom AP, et al.: Bone cancer noma - the effect of coarse fractionation radiotherapy alone or with
pain, Ann NY Acad Sci 1198:173–181, 2010. adjuvant carboplatin therapy, Vet Comp Oncol 3:222–229, 2005.
170. Fan TM, de Lorimier L-P, Charney SC, et al.: Evaluation of IV 193. Kawabe M, Baba Y, Tamai R, et al.: Profiling of plasma metabolites
pamidronate administration in 33 cancer-bearing dogs with pri- in canine oral melanoma using gas chromatography-mass spec-
mary or secondary bone involvement, J Vet Intern Med 19:74–80, trometry, J Vet Med Sci 77:1025–1028, 2015.
2005. 194. Weinstein JI, Payne S, Poulson JM, et al.: Use of force plate analysis
171. Mashiba T, Turner CH, Hirano T, et al.: Effects of suppressed to evaluate the efficacy of external beam radiation to alleviate osteo-
bone turnover by bisphosphonates on microdamage accumulation sarcoma pain, Vet Radiol Ultrasound 50:673–678, 2009.
and biomechanical properties in clinically relevant skeletal sites in 195. Knapp-Hoch HM, Fidel JL, Sellon RK, et al.: An expedited pal-
beagles, Bone 28:524–531, 2001. liative radiation protocol for lytic or proliferative lesions of appen-
172. Burr DB, Allen MR: Mandibular necrosis in beagle dogs treated dicular bone in dogs, J Am Anim Hosp Assoc 45:24–32, 2009.
with bisphosphonates, Orthod Craniofacial Res 12:221–228, 2009. 196. Green EM, Adams WM, Forrest LJ: Four fraction palliative
173. Lundberg AP, Roady PJ, Somrak AJ, et al.: Zoledronate-associated radiotherapy for osteosarcoma in 24 dogs, J Am Anim Hosp Assoc
osteonecrosis of the jaw in a dog with appendicular osteosarcoma, 38:445–451, 2002.
J Vet Intern Med 30:1235–1240, 2016. 197. Sonzogni-Desautels K, Knapp DW, Sartin E, et al.: Effect of cyclo-
174. Fan TM, Lorimier LP De, Garrett LD, et al.: The bone biologic oxygenase inhibitors in a xenograft model of canine mammary
effects of zoledronate in healthy dogs and dogs with malignant oste- tumours, Vet Comp Oncol 9:161–171, 2011.
olysis, J Vet Intern Med 380–387, 2008. 198. Knapp DW, Henry CJ, Widmer WR, et al.: Randomized trial of
175. Milner RJ, Farese J, Henry CJ, et al.: Bisphosphonates and cancer, cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with
J Vet Intern Med 18:597–604, 2004. transitional cell carcinoma of the urinary bladder, J Vet Intern Med
176. Fan TM: Intravenous aminobisphosphonates for managing com- 27:126–133, 2013.
plications of malignant osteolysis in companion animals, Top Com- 199. Kleiter M, Malarkey DE, Ruslander DE, et al.: Expression of cyclo-
panion Anim Med 24:151–156, 2009. oxygenase-2 in canine epithelial nasal tumors, Vet Radiol Ultra-
177. Berenson J, Hirschberg R: Safety and convenience of a 15-minute sound 45:255–260, 2004.
infusion of zoledronic acid, Oncologist 9:319–329, 2004. 200. Flynn AK, Lurie D: Canine acute radiation dermatitis, a survey of
178. Farese JP, Ashton J, Milner R, et al.: The effect of the bisphospho- current management practices in North America, Vet Comp Oncol
nate alendronate on viability of canine osteosarcoma cells in vitro, 5:197–207, 2007.
Vet Comp Oncol 40:113–117, 2004. 201. Miller RC, Le-Rademacher J, Sio TTW, et al.: A phase III, ran-
179. Ashton JA, Farese JP, Milner RJ, et al.: Investigation of the effect domized double-blind study of doxepin rinse versus magic mouth-
of pamidronate disodium on the in vitro viability of osteosarcoma wash versus placebo in the treatment of acute oral mucositis pain in
cells from dogs, Am J Vet Res 66:885–891, 2005. patients receiving head and neck radiotherapy with or without che-
180. Wolfe TD, Pillai SPS, Hildreth BE, et al.: Effect of zoledronic acid motherapy (Alliance A221304), Int J Radiat Oncol 96:938, 2016.
and amputation on bone invasion and lung metastasis of canine 202. Keyerleber MA, Ferrer L: Effect of prophylactic cefalexin treat-
osteosarcoma in nude mice, Clin Exp Metastasis 28:377–389, 2011. ment on the development of bacterial infection in acute radia-
181. Piperno-Neumann S, Le Deley MC, Rédini F, et al.: Zoledronate tion-induced dermatitis in dogs: a blinded randomized controlled
in combination with chemotherapy and surgery to treat osteosar- prospective clinical trial, Vet Dermatol 29:18–37, 2018.
coma (OS2006): a randomised, multicentre, open-label, phase 3 203. Kopf A: Managing a chronic pain patient in the perioperative
trial, Lancet Oncol 17:1070–1080, 2016. period, J Pain Palliat Care Pharmacother 27:394–396, 2013.
182. Milner RJ, Dormehl I, Louw WKA, et al.: Targeted radiother- 204. Reddi D: Preventing chronic postoperative pain, Anaesthesia
apy with Sm-153-EDTMP in nine cases of canine primary bone 71:64–71, 2016.
tumours, J S Afr Vet Assoc 69:12–17, 1998. 205. Horne CE, Engelke MK, Schreier A, et al.: Effects of tactile desen-
183. Barnard SM, Zuber RM, Moore AS: Samarium Sm 153 lexidro- sitization on postoperative pain after amputation surgery, J Peri-
nam for the palliative treatment of dogs with primary bone tumors: anesthesia Nurs 1–10, 2017.
35 cases (1999-2005), J Am Vet Med Assoc 230:1877–1881, 2007. 206. Chaparro LE, Smith SA, Moore RA, et al.: Pharmacotherapy for
184. Lutz S, Balboni T, Jones J, et al.: Palliative radiation therapy for the prevention of chronic pain after surgery in adults, Cochrane
bone metastases: update of an ASTRO evidence-based guideline, Database Syst Rev 7, 2013.
Pr Radiat Oncol 7:4–12, 2017. 207. Mathews KA, Pettifer G, Foster R, et al.: Safety and efficacy of
185. Bregazzi VS, LaRue SM, Powers BE, et al.: Response of feline oral preoperative administration of meloxicam, compared with that of
squamous cell carcinoma to palliative radiation therapy, Vet Radiol ketoprofen and butorphanol in dogs undergoing abdominal sur-
Ultrasound 42:77–79, 2001. gery, Am J Vet Res 62:882–888, 2001.
186. Fidel JL, Sellon RK, Houston RK, et al.: A nine-day accelerated 208. Budsberg SC, Cross AR, Quandt JE, et al.: Evaluation of intrave-
radiation protocol for feline squamous cell carcinoma, Vet Radiol nous administration of meloxicam for perioperative pain manage-
Ultrasound 48:482–485, 2007. ment following stifle joint surgery in dogs, 63:1557–1563, 2002.